GE HealthCare expands global collaborations to help define the future of photon-counting CT with Photonova™ Spectra
- Seven highly respected institutions across three continents will evaluate the clinical applications, quantitative imaging and diagnostic capabilities of GE HealthCare’s next-generation photon-counting CT across diverse clinical settings and care areas
-
These efforts follow Photonova™ Spectra’s CE Mark,
U.S . FDA 510(k) clearance andJapan Pharmaceuticals andMedical Devices Agency regulatory approval, marking the next phase of clinical adoption
Photonova Spectra is
"Deep Silicon photon-counting CT has the potential to change not only what clinicians can see, but what they can understand from every scan – creating new possibilities for early detection, personalized care and diagnostic confidence," shared
Leading institutions expand Photonova Spectra’s research network
Through structured clinical and research programs, a global network of healthcare institutions will evaluate Photonova Spectra across a broad range of clinical applications, assessing image quality, spectral performance, workflow efficiency and diagnostic utility while exploring new opportunities in quantitative imaging, material characterization and ultra-high resolution diagnostics.
These collaborations bring together academic medical centers, specialty hospitals and research institutions with expertise in cardiovascular imaging, quantitative imaging, medical physics and translational research. Their work is intended to generate clinical and technical evidence, expand scientific understanding of Deep Silicon photon-counting CT and provide insights that can inform the continued evolution of Photonova Spectra.
-
Keio University Hospital (Tokyo, Japan ): One ofJapan's premier academic medical centers and a leader in advanced diagnostic imaging and translational research. Researchers will explore quantitative and spectral imaging techniques and emerging clinical applications to better understand Photonova Spectra's potential across future clinical and research use cases.
-
Centro Cardiologico Monzino IRCCS - Istituto di Ricovero e Cura a Carattere Scientifico (
Milan, Italy ): An internationally recognized cardiovascular research and specialty hospital. Investigators will assess Photonova Spectra in cardiovascular imaging while exploring opportunities for quantitative assessment, tissue characterization and workflow considerations relevant to cardiac imaging.
"Cardiovascular disease remains one of the world's leading health challenges, underscoring the need for imaging technologies that enable more informed clinical decision-making," said ProfessorGianluca Pontone , Deputy Scientific Director; Director of theDepartment of Perioperative Cardiology and Cardiovascular Imaging ; and Co-Director of the Sport Cardiology Unit, Centro Cardiologico Monzino IRCCS. "We're excited to work alongsideGE HealthCare to better understand how Photonova Spectra can generate new clinical insights and help support more personalized cardiovascular care."
-
Universitätsspital
Zürich (Zürich, Switzerland ): One of Switzerland’s leading academic medical centers, with internationally recognized expertise in cardiac and hybrid imaging. A research-focused team from itsDepartment of Nuclear Medicine will evaluate Photonova Spectra for coronary CT angiography (CCTA), focusing on how radiation dose can be optimized while maintaining diagnostic performance. The collaboration will also generate clinical and technical insights to help refine imaging protocols, applications and workflow.
“Photon-counting CT offers exciting opportunities to advance coronary imaging by combining high spatial resolution with spectral information,” said ProfessorPhilipp Kaufmann , Director of theDepartment of Nuclear Medicine at UniversitätsspitalZürich . “We aim to determine how best to translate these capabilities into robust, dose-efficient CCTA protocols that support confident clinical decision-making.”
-
University of Wisconsin–Madison (
Madison, Wisconsin ): A globally recognized public research institution known for pioneering work in medical physics and quantitative imaging. Researchers have renewed their collaboration withGE HealthCare to build upon earlier investigations with the photon-counting CT system and explore imaging protocols, quantitative performance and technical measures of image quality to further characterize the technology’s capabilities.
-
Stanford Medicine (
Palo Alto, California ): A leading academic medical center renowned for translating scientific discovery into clinical practice. Its multidisciplinary research team has expanded its collaboration withGE HealthCare and broadened its scope of technical and human-subject studies examining reconstruction methods, image presentation workflows and disease-specific applications, including ultra-high-resolution structural visualization, tissue characterization and potential new imaging biomarkers.
"Our collaboration withGE HealthCare has given our researchers an opportunity to explore how photon-counting CT can be applied across a range of technical and clinical questions,” saidAdam Wang , PhD, Assistant Professor,Department of Radiology and, by courtesy, Electrical Engineering,Stanford University . “We’re excited to continue our work with Photonova Spectra, building on our experience in reconstruction, image analysis and human-subject research to further investigate the capabilities of photon-counting CT and where it may create new opportunities for clinical practice and scientific discovery."
These new and expanding relationships build upon those
-
UZ Brussel –
Vrije Universiteit Brussel (Brussels, Belgium ): A leading European academic medical center, whose team is evaluating Photonova Spectra's advanced cardiac imaging capabilities, including coronary assessment and functional analysis, while generating clinical evidence and refining imaging protocols for routine cardiovascular care.
-
Rigshospitalet (
Copenhagen, Denmark ):Denmark's largest academic hospital and a leading university hospital for highly specialized diagnostics and treatments. Its researchers are investigating broad clinical applications for photon-counting CT, including pediatric and low-dose imaging, tissue characterization and the use of spectral information in complex clinical cases.
Across this global research network,
For more information about Photonova Spectra, visit gehealthcare.com.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.
| ___________________________ |
|
i Photonova Spectra is CE marked and 510(k) cleared with the |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116791842/en/
GE HealthCare Media Contact:
M +1 608 381 8829
margaret.steinhafel@gehealthcare.com
Source: